Barbara Ann Burtness, MD

Professor of Medicine (Medical Oncology); Clinical Research Program Leader, Head and Neck Cancers Program ; Co-Director, Developmental Therapeutics Research Program

Research Interests

Chemicals and Drugs; Analytical, Diagnostic and Therapeutic Techniques and Equipment

Research Organizations

Cancer Center, Yale: Developmental Therapeutics

Medical Oncology: Subset Medical Oncology Faculty

Research Summary

Studies of targeted treatments for EGFR expressed head and neck cancers. She has shown that high EGFR expression predicted resistance to cetuximab in head and neck cancers and is the principal investigator of a phase I clinical trial of cetuximab with escalating doses of the mTOR inhibitor everolimus to target signaling from pAkt, and an investigator-initiated phase II trial of chemotherapy plus cetuximab, followed by addition of erlotinib.

Extensive Research Description

Studies of targeted treatments for EGFR expressed head and neck cancers. She has shown that high EGFR expression predicted resistance to cetuximab in head and neck cancers and is the principal investigator of a phase I clinical trial of cetuximab with escalating doses of the mTOR inhibitor everolimus to target signaling from pAkt, and an investigator-initiated phase II trial of chemotherapy plus cetuximab, followed by addition of erlotinib.

Selected Publications

Edit this profile

Contact Info

Barbara Ann Burtness, MD
Patient Care Location
Yale Cancer CenterSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste NP - 4

New Haven, CT 06511
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028